Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
Study results above support the assumption that biologically interactive protein nanoparticle enhances the corrective potential of taxane therapy.
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. (APP) (NASDAQ: APPX) today said that results from a 106 self-possessed Phase II study of ABRAXANE in patients with advanced breast cancer whose malady had progressed while they were being treated with TAXOL® and Taxotere® responded to subsequent treatment with ABRAXANETM (albumin nanoparticle paclitaxel). The results were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chic Orleans, LA, by Joanne Blum, M.D., Ph.D., of the Charles A. Sammons Cancer Center, Baylor University Medical Center in Dallas, TX, one of 38 US Oncology affiliated practices that had patients participate in this clinical muse about of ABRAXANE.
The Withdraw II study, sponsored by American BioScience, included 106 patients with reformist metastatic breast cancer whose disability had progressed while being treated with TAXOL or Taxotere in the metastatic setting, or had a retreat within 12 months of adjuvant taxane therapy. The patients enrolled in this study had a very poor prophecy, with 91% having visceral (lung and liver) malady, 65% with more than three metastatic sites, and 88% demonstrating ongoing tumor nurturing while receiving TAXOL and/or Taxotere in the metastatic setting. Evidence of the bustle of weekly doses of ABRAXANE in this highly refractory residents is provided by the following findings:
– A 15% overall retort rate (95% CI: 8%-22%) in the 106 patients studied with a 38% probability of survival at 12 months based on analysis of evidence to assignation;
– 40% of patients on treatment with ABRAXANETM were free of plague order due to the fact that as extended as four months; and almost 30% for as long as six months;
– Of those patients who progressed while on Taxotere solitary in the metastatic setting (n=33), a 24% response deserve was well-known after receiving weekly ABRAXANETM;
– Of those patients who progressed while on TAXOL abandoned in the metastatic mise en scene (n= 31), a 16% response rate was distinguished after receiving weekly ABRAXANE.
“The demonstration that 15% of patients responded to ABRAXANETM treatment and that 30% had no infirmity progress after six months in this powerfully refractory breast cancer population that had progressed even while on TAXOL and/or Taxotere is an important finding. I recollect this drug has significant potential to benefit women with core cancer,” said Edith Perez, director of the breast cancer program at the Mayo Clinic in Jacksonville, FL.
The tolerability of this weekly regimen was demonstrated by the finding of
Carrie Jiminez